Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Shares of Seres Therapeutics plummeted more than 69 percent Friday after its microbiome treatment for preventing a bacterial infection failed in a mid-stage study and raised doubts about this growing area of research.
The product, known as SER-109, is a mix of bacterial spores designed to treat patients from recurring infection of the potentially deadly bacterium Clostridium difficile, or C. diff.
In a phase 2 study, SER-109 did not reduce the risks associated with the infection, compared to the placebo, at up to eight weeks of treatment.
Seres Chairman and CEO Roger Pomerantz said, in a press release, that the clinical results were "unexpected" in view of positive data in prior investigations and supporting clinical data.
"Specifically, the recurrence rates observed in the overall SER-109 treatment group, in the age stratified subgroups, and in the placebo groups are inconsistent with our expectations," he said. "Our priority is to complete a full review of the clinical results and microbiome data of the phase 2 study and to compare it to data from the prior investigator sponsored Phase 1b."
Seres said it will continue to gather and analyze study data, and in consultation with the U.S. Food and Drug Administration, make appropriate adjustments to its SER-109 development plans.
However, investors saw the results as potentially warning about the entire area of microbiome therapeutics, which has been looked on with much promise. The burgeoning field looks to treat illnesses by adding "good" bacteria to your digestive tract.
Seres is one of several companies racing to do that. Others include Vedanta Biosciences, Enterome, Second Genome and uBiome.
The spokesman for Seres didn't immediately respond for CNBC's request for comment.
MCRB 2016 Stock
Correction: An earlier version mischaracterized EpiBiome's approach to microbiome therapeutics.